<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl0002">
 <label>Table 2</label>
 <caption>
  <p>Vaccine platforms against SARS-CoV-2.</p>
 </caption>
 <alt-text id="alt0003">Table 2</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top">Vaccine technologies</th>
    <th valign="top">Principle</th>
    <th valign="top">Advantage</th>
    <th valign="top">Disadvantage</th>
    <th valign="top">Clinical trials stage</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top">mRNA-based</td>
    <td valign="top">Delivery of modified mRNA</td>
    <td valign="top">Scalable production
     <break/>Cytoplasmic 
     <break/>No vector or foreign DNA
     <break/>Two or more antigens
     <break/>Self-amplifying mRNAs provide sustained expression
     <break/>Cellular and humoral responses
    </td>
    <td valign="top">Stringent preparation/storage
     <break/>Less stable
     <break/>Low efficiency of delivery
     <break/>Transient expression (except SAM) 
     <break/>Fortuitous immune response
     <break/>Cost
    </td>
    <td valign="top">Phase 3</td>
   </tr>
   <tr>
    <td valign="top">DNA-based</td>
    <td valign="top">Vector-based delivery of a viral gene</td>
    <td valign="top">Easy to generate and stable 
     <break/>Storage at room temperature
     <break/>Scalable
     <break/>Cellular and humoral responses
     <break/>Two or more antigens
     <break/>No adjuvant
     <break/>Ease of delivery
     <break/>Low cost
    </td>
    <td valign="top">Issues associated with a vector DNA, such as immunogenicity and genomic integration and pre-existing immunity
     <break/>Purity
     <break/>Pathogenicity due to recombination with wild type virus
    </td>
    <td valign="top">Phase 2</td>
   </tr>
   <tr>
    <td valign="top">Peptide-based</td>
    <td valign="top">A fragment or whole length viral peptide</td>
    <td valign="top">Non-infectious
     <break/>Robust immune response
     <break/>Safe
     <break/>Ease of delivery
    </td>
    <td valign="top">Challenging manufacturing
     <break/>Stability
     <break/>Need for adjuvant
    </td>
    <td valign="top">Phase 2</td>
   </tr>
   <tr>
    <td valign="top">Live attenuated virus</td>
    <td valign="top">De-optimization of the genome (to reduce pathogenicity)</td>
    <td valign="top">Multiple viral antigens
     <break/>Strong immune response
    </td>
    <td valign="top">Safety concerns
     <break/>Labor intensive
     <break/>
    </td>
    <td valign="top">Phase I</td>
   </tr>
   <tr>
    <td valign="top">Inactivated virus</td>
    <td valign="top">Chemically or UV inactivated virus</td>
    <td valign="top">Relatively simple
     <break/>Strong immune response
    </td>
    <td valign="top">Risk of partial inactivation
     <break/>Risk of becoming pathogenic
    </td>
    <td valign="top">Phase I</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
